Although Healius’ [ASX:HLS] shares have risen 20.9% since announcing last month the AUD 500m sale of its medical centres unit to BGH Capital, the company is still trading at a discount to peers Sonic Healthcare [ASX:SHL] and Integral Diagnostics [ASX:IDX].
The sale of the medical centres business is designed to simplify Healius’ portfolio and turn it into a specialist diagnostic and day hospitals business. It is feasible that Healius could be valued more in line with its peers.
Sonic Healthcare and Integral Diagnostics which are currently trading at 15.50x and 17.29x EV/TTM EBITDA, respectively, while Healius is trading at a pro-forma EV/TTM EBITDA of just 12.31x.
Meanwhile, Healius is still subject to an indicative AUD 3.4 p/s offer from Partners Group. The offer, which Healius, in March, said neither reflected the fundamental value of the company nor represented compelling value to warrant the granting of exclusive due diligence, would value the business at 13.39x TTM EBITDA – still below the trading level of its peers.
To view the full story, click here.
If you are not subscribed to Dealreporter, please contact Hamish Miers for a free trial in order to access the full article.
by Vivian Wong